ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Synthego, a start-up that sells CRISPR gene-editing tool kits and CRISPR-edited cells to researchers, raised $110 million in series C financing last week from the venture capital firms Founders Fund, 8VC, and Menlo Ventures. The start-up is using automation and machine learning to quickly scale up the production of customized CRISPR kits and engineered cells. Chief Operating Officer Ted Tisch says Synthego’s goal is to help lower the cost of cell and gene therapies from hundreds of thousands of dollars to thousands of dollars.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X